Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
about
Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidatesReplacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteinsIdentification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypesCytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions.Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccineA recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates.Envelope targeting: hemagglutinin attachment specificity rather than fusion protein cleavage-activation restricts Tupaia paramyxovirus tropism.Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropismProgress in the development of human parainfluenza virus vaccinesHeterologous exchanges of the glycoprotein and the matrix protein in a Novirhabdovirus.Recombinant wild-type and edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificityNonsegmented negative-strand viruses as vaccine vectors.Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animalsMumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles.Respiratory viral infections detected by multiplex PCR among pediatric patients with lower respiratory tract infections seen at an urban hospital in Delhi from 2005 to 2007A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates.Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability.Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vectorDevelopment of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins.
P2860
Q27469676-830A5951-3F83-4E11-A327-0E4D68E2371CQ27469749-3030B971-8AD6-42EA-BC08-45507B2056B8Q30708312-79C7850D-5620-42BA-877F-2A617C321156Q33641383-0680E01A-8452-411C-9D45-4EF490B6424EQ33782252-31E15120-904E-4878-B803-186DB5CC6A78Q33786023-CEA89A25-3FC3-4F9E-8A0E-0C4E8726F03BQ33793103-B17EFE25-20E6-4278-B217-25F6BAE4304DQ33801293-4BED665B-2B9E-451C-8AC4-8F0446138330Q33911962-117468BE-BF7D-4A06-AAD4-28458821403BQ34190714-BC467C11-1DC2-4267-991F-8C763B65E4C5Q34209872-19A9927F-12F4-4947-8C05-BCAC349E1A83Q34332631-E423B8C9-C883-4867-ACEF-D94C0E0FDFFDQ34338440-CE354FBD-B603-4025-AA3A-22C7F20D3AD1Q35139219-2FF8CD51-4D14-43D3-9DF7-2C314CED5EC1Q35285887-AF95EB0D-BE67-4081-B034-ABE0F61D580CQ36844471-8232B752-3F2E-4595-89D3-94DC48C3E6DDQ37247965-3F737D6E-8AFB-4678-BC97-14AB27D9FFB6Q37259952-B51CC5C4-A266-4B10-9368-4CE192CD1F2DQ37468212-9757AEE8-8650-475B-9D1E-698C1B140A03Q39539804-CBB66D61-9733-4502-9234-11ADDCC55DEFQ39593656-29F36BF3-7F8E-45C8-A861-9CBCEFF610ADQ41890251-BD2E48FF-697F-4545-9139-ABE227ECF930
P2860
Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1.
description
1998 nî lūn-bûn
@nan
1998 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@ast
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@en
type
label
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@ast
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@en
prefLabel
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@ast
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@en
P2093
P2860
P1433
P1476
Recovery of a fully viable chi ...... placed by those of PIV type 1.
@en
P2093
P2860
P304
P577
1998-04-01T00:00:00Z